Bob Langer Answers Your Webinar Questions
Bob Langer answers select audience questions from the GEN Biotechnology webinar hosted on December 16, 2023.
Bob Langer answers select audience questions from the GEN Biotechnology webinar hosted on December 16, 2023.
The landscape of novel monoclonal antibody (mAb) therapeutic formats has expanded significantly in recent years, introducing new challenges in the purification process. Traditional full-length IgG…
The study showed that DNA damage in response to stimuli triggers an inflammation pathway that prompts activity in memory-encoding neurons.
Depleting myeloid-biased HSCs in aged mice restored features of a more youthful immune system, while reducing age-related markers of immune decline
Phase I/IIa data for a single dose of REGENEXBIO’s gene therapy, RGX-314, shows promise for treating wet age-related macular degeneration.
Delivering nucleic acids using lipid nanoparticles (LNPs) to target cells has tremendous potential to enable the development of new cell and gene therapies as well…
Lonza’s new offering provides manufacturing of spray-dried protein formulations, nucleotide-based drugs, and peptides.
Step toward an HIV cure: a “shock and kill” virus-like particle shows promise as latency reversal agent in blood samples from chronic HIV patients.
Scientists have engineered multi-tailed mRNAs that produce up to 20x more protein and last up to 3x longer than unmodified mRNA.
Step toward an HIV cure: a “shock and kill” virus-like particle shows promise as latency reversal agent in blood samples from chronic HIV patients.
Subvisible aggregates are a critical quality attribute (CQA) and a key measure of physical stability for all biologics. Aggregates are comprised of proteins that have…